Savara (SVRA) Set to Release Earnings on Wednesday

Savara (NASDAQ:SVRA) will likely be announcing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Savara to post earnings of ($0.1633) per share and revenue of $0.50 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:00 PM ET.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). On average, analysts expect Savara to post ($0.66) EPS for the current fiscal year and ($0.32) EPS for the next fiscal year.

Savara Stock Up 0.4%

NASDAQ SVRA opened at $4.75 on Wednesday. Savara has a 1-year low of $3.86 and a 1-year high of $7.01. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The business’s fifty day moving average price is $5.04 and its 200-day moving average price is $5.39.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Royal Bank Of Canada set a $10.00 price objective on Savara in a research report on Wednesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Thursday, October 15th. Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Citigroup restated a “market outperform” rating on shares of Savara in a research note on Wednesday, October 7th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Savara in a research report on Wednesday, October 7th. They set an “overweight” rating and a $12.00 price target for the company. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Savara has an average rating of “Moderate Buy” and a consensus price target of $10.25.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s work is centered on conditions with significant unmet medical needs, particularly diseases involving impaired lung function and abnormal accumulation of material in the lungs.

Savara’s lead product candidate is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder in which surfactant accumulates in the airspaces and interferes with breathing.